Advertisement

AIDS and Behavior

, Volume 18, Issue 3, pp 443–451 | Cite as

Combined HIV Prevention, the New York City Condom Distribution Program, and the Evolution of Safer Sex Behavior Among Persons Who Inject Drugs in New York City

  • D. C. Des JarlaisEmail author
  • K. Arasteh
  • C. Mcknight
  • J. Feelemyer
  • H. Hagan
  • H. L. F. Cooper
  • D. C. Perlman
Original Paper

Abstract

Examine long term sexual risk behaviors among persons who inject drugs (PWID) in New York City following implementation of “combined” prevention programming, including condom social marketing. Quantitative interviews and human immunodeficiency virus (HIV) testing were conducted among PWID entering Beth Israel Medical Center drug treatment programs 1990–2012. Data were analyzed by four time periods corresponding to the cumulative implementation of HIV prevention interventions. 7,132 subjects were recruited from 1990 to 2012; little change in sexual behavior occurred among HIV seronegative subjects, while HIV seropositive subjects reported significant decreases in being sexually active and significant increases in consistent condom use. HIV transmission risk (being HIV positive and engaging in unprotected sex) declined from 14 % in 1990–1995 to 2 % in 2007–2012 for primary sexual partners and from 6 to 1 % for casual partners. Cumulative implementation of combined prevention programming for PWID was associated with substantial decreases in sexual risk behavior among HIV seropositives.

Keywords

Condom/condom promotion Combined prevention HIV Heterosexual transmission Persons who inject drugs Harm reduction 

Notes

Acknowledgments

This work was grant funded by 5R01DA003574.

Conflict of interest

The authors disclose no financial conflicts of interest.

References

  1. 1.
    World Health Organization UNODC, Joint United Nations Programme on HIV/AIDS. Technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users. Geneva: 2008.Google Scholar
  2. 2.
    Sendziuk P. Harm reduction and HIV-prevention among injecting drug users in Australia: an international comparison. Can Bull Med Hist/Bulletin canadien d’histoire de la médecine. 2007;24(1):113–29.Google Scholar
  3. 3.
    Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet. 2010;376(9737):285–301.PubMedCrossRefGoogle Scholar
  4. 4.
    Van den Berg C, Smit C, Van Brussel G, Coutinho R, Prins M. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction. 2007;102(9):1454–62.CrossRefGoogle Scholar
  5. 5.
    de Vos AS, van der Helm JJ, Prins M, Kretzschmar MEE. Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam: evidence for harm reduction? Paper presented at: International AIDS Conference 2012; Washington D.C.Google Scholar
  6. 6.
    Des Jarlais DC, Arasteh K, McKnight C, et al. HIV infection during limited versus combined HIV prevention programs for IDUs in New York City: the importance of transmission behaviors. Drug Alcohol Depend. 2010;109(1):154–60.PubMedCrossRefGoogle Scholar
  7. 7.
    Montaner J, Lima VD, Yip B, Day I, et al. Expanded HAART coverage is associated with decreased HIV/AIDS morbidity and HIV new diagnoses: an update on the ‘treatment as prevention’ experience in British Columbia, Canada. Paper presented at: International AIDS Conference 2012; Washington D.C.Google Scholar
  8. 8.
    Kral AH, Bluthenthal RN, Lorvick J, Gee L, Bacchetti P, Edlin BR. Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis. Lancet. 2001;357(9266):1397–401.PubMedCrossRefGoogle Scholar
  9. 9.
    Strathdee SA, Sherman SG. The role of sexual transmission of HIV infection among injection and non-injection drug users. J Urban Health. 2003;80(4):iii7–14.PubMedCentralPubMedGoogle Scholar
  10. 10.
    Des Jarlais DC, Arasteh K, McKnight C, et al. HIV infection during limited versus combined HIV prevention programs for IDUs in New York City: the importance of transmission behaviors. Drug Alcohol Depend. 2010;109(1–3):154–60.PubMedCrossRefGoogle Scholar
  11. 11.
    Newman RG, Cates MS. Methadone treatment in narcotic addiction: program management, findings, and prospects for the future. New York: Academic Press; 1977.Google Scholar
  12. 12.
    Des Jarlais DC, Perlis T, Arasteh K, et al. HIV incidence among injection drug users in New York City, 1990 to 2002: use of serologic test algorithm to assess expansion of HIV prevention services. Am J Public Health. 2005;95(8):1439–44.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Heller D, Paone D. Access to sterile syringes for injecting drug users in New York City: politics and perception (1984–2010). Subst Use Misuse. 2011;46(2–3):140–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Des Jarlais DC, Arasteh K, Friedman SR. HIV among drug users at Beth Israel Medical Center, New York City, the first 25 years. Subst Use Misuse. 2011;46(2–3):131–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Henman AR, Paone D, Des Jarlais DC, Kochems LM, Friedman SR. Injection drug users as social actors: a stigmatized community’s participation in the syringe exchange programmes of New York City. AIDS Care. 1998;10(4):397–408.PubMedCrossRefGoogle Scholar
  16. 16.
    Fuller CM, Galea S, Caceres W, Blaney S, Sisco S, Vlahov D. Multilevel community-based intervention to increase access to sterile syringes among injection drug users through pharmacy sales in New York City. Am J Public Health. 2007;97(1):117–24.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Deren S, Hagan H, Friedman S, et al. Current and emerging research needs in studying the NYC HIV-drug use epidemic. Subst Use Misuse. 2011;46(2–3):316–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Lert F, Kazatchkine MD. Antiretroviral HIV treatment and care for injecting drug users: an evidence-based overview. Int J Drug Policy. 2007;18(4):255–61.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    New York City Department of Health and Mental Hygiene. HIV Surveillance & Epidemiology Program—HIV/AIDS Annual Surveillance Statistics. New York City: NYCDOHMH;1982–2013.Google Scholar
  20. 20.
    Chiasson MA, Berenson L, Li W, et al. Declining HIV/AIDS mortality in New York city. JAIDS. 1999;21(1):59–64.PubMedGoogle Scholar
  21. 21.
    Messeri P, Lee G, Abramson DM, Aidala A, Chiasson MA, Jessop DJ. Antiretroviral therapy and declining AIDS mortality in New York City. Med Care. 2003;41(4):512–21.PubMedGoogle Scholar
  22. 22.
    Wong T, Chiasson M, Reggy A, Simonds R, Heffess J, Loo V. Antiretroviral therapy and declining AIDS mortality in New York City. J Urban Health. 2000;77:492–500.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Burke RC, Wilson J, Bernstein KT, et al. The NYC Condom: use and acceptability of New York City’s branded condom. Am J Public Health. 2009;99(12):2178–80.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Burke RC, Wilson J, Kowalski A, et al. NYC Condom use and satisfaction and demand for alternative condom products in New York City sexually transmitted disease clinics. J Urban Health. 2011;88(4):749–58.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Des Jarlais DC, McKnight CM, Arasteh K, et al. Use of the “NYC Condom” among people who use drugs. J Urban Health. (in press).Google Scholar
  26. 26.
    Des Jarlais DC, Friedman SR, Novick DM, et al. HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987. JAMA. 1989;261(7):1008–12.PubMedCrossRefGoogle Scholar
  27. 27.
    Des Jarlais DC, Arasteh K, Hagan H, McKnight C, Perlman DC, Friedman SR. Persistence and change in disparities in HIV infection among injection drug users in New York City after large-scale syringe exchange programs. Am J Public Health. 2009;99(S2):S445–51.PubMedCrossRefGoogle Scholar
  28. 28.
    Des Jarlais DC, Perlis T, Arasteh K, et al. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990–2001. AIDS. 2005;19:S20–5.PubMedCrossRefGoogle Scholar
  29. 29.
    Stata 12 [computer program]. College Station, Texas 2012.Google Scholar
  30. 30.
    Des Jarlais DC, Bramson HA, Wong C, et al. Racial/ethnic disparities in HIV infection among people who inject drugs: an international systematic review and meta-analysis. Addiction. 2012;107(12):2087–95.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Parsons JT, Schrimshaw EW, Wolitski RJ, et al. Sexual harm reduction practices of HIV-seropositive gay and bisexual men: serosorting, strategic positioning, and withdrawal before ejaculation. AIDS. 2005;19:S13–25.PubMedCrossRefGoogle Scholar
  32. 32.
    MacKellar DA, Hou SI, Whalen CC, et al. HIV/AIDS complacency and HIV infection among young men who have sex with men, and the race-specific influence of underlying HAART beliefs. Sex Transm Dis. 2011;38(8):755–63.PubMedGoogle Scholar
  33. 33.
    Des Jarlais DC, Perlis T, Friedman SR, et al. Declining seroprevalence in a very large HIV epidemic: injecting drug users in New York City, 1991 to 1996. Am J Public Health. 1998;88(12):1801–6.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Des Jarlais DC, Perlis T, Arasteh K, et al. “Informed altruism” and “partner restriction” in the reduction of HIV infection in injecting drug users entering detoxification treatment in New York City, 1990–2001. JAIDS. 2004;35(2):158–66.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • D. C. Des Jarlais
    • 1
    Email author
  • K. Arasteh
    • 1
  • C. Mcknight
    • 1
  • J. Feelemyer
    • 1
  • H. Hagan
    • 2
  • H. L. F. Cooper
    • 3
  • D. C. Perlman
    • 1
  1. 1.Beth Israel Medical CenterThe Baron Edmond de Rothschild Chemical Dependency InstituteNew YorkUSA
  2. 2.College of NursingNew York UniversityNew YorkUSA
  3. 3.Rollins School of Public Health at Emory UniversityAtlantaUSA

Personalised recommendations